Association between distance to community health care facilities and COVID-19–related mortality across U.S. counties in the COVID-19–vaccine era

Huang, Weijian; Hernandez, Inmaculada; Tang, Shangbin; Dickson, Sean; Berenbrok, Lucas A.; Guo, Jingchuan

doi:10.1186/s13104-023-06366-3

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Income inequality also has played a substantial role in shaping the impact of COVID-19 (Yao et al, 2022). Low-income individuals often have limited access to healthcare (Huang et al 2023), live in crowded conditions, and work in jobs that expose them to higher risks of infection (Stojkoski et al, 2020). These socioeconomic factors make it more difficult for disadvantaged populations to protect themselves from the virus and access timely medical care when needed (Huang et al 2023, Sá 2020, Stojkoski et al, 2020.…”

Section: Introductionmentioning

confidence: 99%

“…Low-income individuals often have limited access to healthcare (Huang et al 2023), live in crowded conditions, and work in jobs that expose them to higher risks of infection (Stojkoski et al, 2020). These socioeconomic factors make it more difficult for disadvantaged populations to protect themselves from the virus and access timely medical care when needed (Huang et al 2023, Sá 2020, Stojkoski et al, 2020. Countries with higher income disparities have experienced more significant variations in COVID-19 death rates (Yao et al, 2022).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19 Mortality Through the Inequality Lens: The Impact of Obesity, Age, and Income Across Countries and Time

Barrera,

Barnor,

Miljkovic

et al. 2024

Preprint

View full text Add to dashboard Cite

This study examines COVID-19 mortality inequalities among 171 countries, analyzing the impact of obesity, age, and income on mortality. We employ three temporal snapshots of COVID-19 attributable deaths: cumulative deaths until December 1, 2020, August 1, 2021, and February 1, 2022. Utilizing innovative metrics, such as the COVID-19 Mortality Inequality Curve, the COVID-19 Mortality Inequality Index (CMII), and the Theil Index, we offer comprehensive insights into the distribution of COVID-19-related deaths across different demographics and socioeconomic groups. Our findings reveal those countries with higher obesity rates and a larger elderly population face significantly higher COVID-19 mortality rates. Contrary to initial expectations, income-based disparities were relatively low at the outset and remained stable throughout the study period, underscoring the pandemic's complex and multifaceted nature. Obesity is identified as a crucial determinant of COVID-19 mortality inequalities. The results highlight the critical need for promoting and ensuring equitable vaccine distribution, particularly in regions vulnerable due to high rates of obesity and significant elderly populations. The study challenges previous assumptions about the role of income in influencing COVID-19 mortality outcomes at the international level, emphasizing the need for targeted public health interventions. JEL Classification: I14, I18, Q18

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

COVID-19 Mortality Through the Inequality Lens: The Impact of Obesity, Age, and Income Across Countries and Time

Barrera,

Barnor,

Miljkovic

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Current challenges of COVID-19 disease include limited access to vaccines and medications (5), reduced diagnostic testing to assess the true remaining impact of the disease (6), and increased susceptibility of vulnerable populations (i.e., increased age, comorbidities, and social deprivation) to severe disease (6,7). Numerous drugs have been shown to be safe and effective in treating patients with severe COVID-19 (i.e., corticosteroids, baricitinib, or IL-6 receptor blockers) (8), but few have been shown to prevent disease progression.…”

Section: Introductionmentioning

confidence: 99%

Regional moderate hyperthermia for mild-to-moderate COVID-19 (TherMoCoV study): a randomized controlled trial

Mancilla-Galindo,

Kammar-García,

Mendoza-Gertrudis

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundTo prevent COVID-19 progression, low-cost alternatives that are available to all patients are needed. Diverse forms of thermotherapy have been proposed to prevent progression to severe/critical COVID-19.ObjectiveThe aim of this study is to evaluate the efficacy and safety of local thermotherapy to prevent disease progression in hospitalized adult patients with mild-to-moderate COVID-19.MethodsA multicenter, open-label, parallel-group, randomized, adaptive trial is used to evaluate the efficacy and safety of local thermotherapy to prevent disease progression in hospitalized adult patients with mild-to-moderate COVID-19. Eligible hospitalized adult patients with symptoms of COVID-19 with ≤5 days from symptom onset, meeting criteria for mild or moderate COVID-19, were randomly assigned to the intervention consisting of local thermotherapy via an electric heat pad in the thorax (target temperature range 39.5–42°C) continuously for 90 min, twice daily, for 5 days, or standard care. The main outcome was the proportion of patients who progressed to severe-to-critical COVID-19 or death. Patients were randomized in a 1:1 ratio through a centralized computer-generated sequence of minimization with a random component of 20%. Participants and medical staff were not blinded to the intervention.ResultsOne-hundred and five participants (thermotherapy n = 54, control n = 51) with a median age of 53 (IQR: 41–64) years were included for analysis after the early cessation of recruitment due to the closure of all temporal COVID-19 units (target sample size = 274). The primary outcome of disease progression occurred in 31.4% (16/51) of patients in the control group vs. 25.9% (14/54) of those receiving thermotherapy (risk difference = 5.5%; 95%CI: −11.8–22.7, p = 0.54). Thermotherapy was well tolerated with a median total duration of thermotherapy of 900 (IQR: 877.5–900) min. Seven (13.7%) patients in the control group and seven (12.9%) in the thermotherapy group had at least one AE (p = 0.9), none of which were causally attributed to the intervention. No statistically significant differences in serum cytokines (IL-1β, IL-6, IL-8, IL-10, IL-17, and IFN-γ) were observed between day 5 and baseline among groups.ConclusionLocal thermotherapy was safe and well-tolerated. A non-statistically significant lower proportion of patients who experienced disease progression was found in the thermotherapy group compared to standard care. Local thermotherapy could be further studied as a strategy to prevent disease progression in ambulatory settings.Clinical Trial registration: www.clinicaltrials.gov, identifier: NCT04363541.

show abstract

Prolonged travel time to transplantation center is associated with poor outcomes following heart transplantation

Suarez-Pierre,

Zakrzewski,

Anigbogu

et al. 2023

The American Journal of Surgery

View full text Add to dashboard Cite

Association between distance to community health care facilities and COVID-19–related mortality across U.S. counties in the COVID-19–vaccine era

Cited by 4 publications

References 21 publications

COVID-19 Mortality Through the Inequality Lens: The Impact of Obesity, Age, and Income Across Countries and Time

COVID-19 Mortality Through the Inequality Lens: The Impact of Obesity, Age, and Income Across Countries and Time

Regional moderate hyperthermia for mild-to-moderate COVID-19 (TherMoCoV study): a randomized controlled trial

Prolonged travel time to transplantation center is associated with poor outcomes following heart transplantation

Contact Info

Product

Resources

About